Search clinical trials for: ADX-102, Sjögren-Larsson Syndrome

Total 39418 results

Aldeyra Therapeutics, Inc.

Completed

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

Sjogren-Larsson Syndrome

United States
Aldeyra Therapeutics, Inc.
ORA, Inc.

Completed

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Conjunctivitis, Allergic

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Dry Eye Syndromes

Canada
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Dry Eye Syndromes

United States
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Allergic Conjunctivitis

Canada
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Aldeyra Therapeutics, Inc.

Completed

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

Non-infectious Anterior Uveitis

United States
University of Nebraska

Recruiting

ADX-629 Therapy for Sjogren-Larsson Syndrome

Sjogren-Larsson Syndrome

United States
Q32 Bio Inc.

Recruiting

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

Atopic Dermatitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Atopic Asthma

Canada
Q32 Bio Inc.

Completed

Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers

Safety Issues

Australia
Aldeyra Therapeutics, Inc.

Withdrawn

Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Nephrotic Syndrome

United States
ADARx Pharmaceuticals, Inc.
ADARx Australia Pty Ltd

Recruiting

Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Australia
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

Ethanol Intoxication

United States
Aldeyra Therapeutics, Inc.

Recruiting

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Atopic Dermatitis

United States
Q32 Bio Inc.

Not yet recruiting

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

IgA Nephropathy | Lupus Nephritis (LN) | C3 (Complement Component 3) Glomerulopathy
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Aldeyra Therapeutics, Inc.

Recruiting

A Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease

Dry Eye Disease

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Aldeyra Therapeutics, Inc.

Completed

An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease

Dry Eye

Canada
ADARx Pharmaceuticals, Inc.

Recruiting

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Hereditary Angioedema

Australia
Q32 Bio Inc.
Innovaderm Research Inc.

Active, not recruiting

Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Alopecia Areata

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Chronic Cough

United States
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

Covid19

United States
Jazz Pharmaceuticals

Completed

A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness

Narcolepsy

United States
Jazz Pharmaceuticals

Completed

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Narcolepsy

United States
Aldeyra Therapeutics, Inc.

Recruiting

A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease

Dry Eye Disease

Canada
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States
Alzeca Biosciences, Inc.
pharmtrace klinische Entwicklung GmbH

Recruiting

Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease

Alzheimer Disease

Germany
ContraFect

Completed

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

Staphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis

United States, Belgium, Bulgaria, Chile, Czechia, France, Germany, Greece, Guatemala, Israel, Italy, Russian Federation, Spain, United Kingdom
Arquer Diagnostics Ltd

Recruiting

A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Bladder Cancer

United States
Yeditepe University Hospital

Completed

Prevention of Nausea and Vomiting in Patients After Surgery

Postoperative Nausea and Vomiting

Turkey
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
China Medical University, China

Not yet recruiting

TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

Fruquintinib | Regorafenib | Gastrointestinal Tumours | TAS 102
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

Canada
Yeditepe University Hospital

Completed

Prevention of Propofol Injection Pain (VRS)

Pain

Turkey
Aldeyra Therapeutics, Inc.

Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Neothetics, Inc

Completed

A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

Weight

United States
University of Shizuoka
White Cross Nursing Home; Seirei Hamamatsu General Hospital; Shizuoka General...

Completed

Catechin Gargling for Influenza Infection

Influenza Infection

Japan
Medical University of Warsaw

Unknown

Expression of MCM5 in Urine in Patients With Urothelial Cancers

Bladder Cancer

Poland
CinDome Pharma, Inc.

Completed

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Gastroparesis

United States
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability Study With Single Ascending Doses of ODM-102

Healthy Volunteers

Finland
Conceptra Biosciences, LLC

Recruiting

CCT-102 vs. Expectant Management in Delayed Pregnancy Loss (MERMAID)

Early Pregnancy Loss, Delayed Pregnancy Loss

United States
Ultragenyx Pharmaceutical Inc

Not yet recruiting

Long-term Extension of GTX-102 in Angelman Syndrome

Angelman Syndrome

United States, Australia, Canada, Germany, United Kingdom, Israel, France, Spain
Ultragenyx Pharmaceutical Inc

Active, not recruiting

A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome

Angelman Syndrome

United States, United Kingdom, Canada, Australia, France, Germany, Spain, Israel

3

Subscribe